Beyhan Zaim BS, MBA

Ms. Zaim is the global head for Alzheimer’s Disease (AD) at Eisai where she develops strategies to progress the commercial development of Eisai's existing and future AD assets and heads the collaborative efforts of internal and external stakeholders to maximize the value of the AD portfolio. She also leads Eisai's Neurology Commercial Development team in creating and driving commercial strategies for other neurology early pipeline assets and late stage compounds approaching the commercialization stage.
Prior to joining Eisai in April 2016, Ms. Zaim spent 20-plus years at Pfizer where she held diverse global positions encompassing global marketing, strategic planning, new business development and country management. She held a number of international assignments, including Asia Business Development Director based in Hong Kong and Country Manager of Thailand. Among her key roles at Pfizer were serving as Vice President of External Opportunities and New Business; Vice President of Commercial Development Primary Care Business Unit; Vice President, Medicine Team Leader; and Group Leader, Neurosciences, Worldwide Marketing.
During her career at Pfizer, she oversaw the global launches of several blockbuster products such as Spiriva, Lyrica and Eliquis. Ms. Zaim holds a Master of Business Administration degree from Columbia Business School, the business school of Columbia University located in Manhattan, New York City. She earned her Bachelor of Science degree from the Rutgers School of Pharmacy.